LEXINGTON, Mass.--(BUSINESS WIRE)--T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the U.S. Patent and Trademark Office has issued two patents adding depth and breadth to the Company’s intellectual property portfolio. These patents cover both the device and methods related to the Company’s flagship T2Candida assay and the detection of additional biological analytes, including specific drug and biomarker targets, in biological samples using the T2MR platform.
